Becerra VG, Carrillo NG, Plascencia A, Rivera MCC, Velarde RF, Domínguez HM, Hernández CII

Language: Spanish
References: 11
Page: 142-144
PDF size: 78.95 Kb.

ABSTRACT

Background. The strains of the genus Candida have currently acquired importance as pathogens in nosocomial infections because of their ability to generate resistance. Echinocandins are a group of antifungals of recent use, but the automated equipment still does not observe the determination of minimum inhibitory concentration (MIC) for these drugs.
Material and method. We isolated 10 strains of the genus Candida resistant to fluconazole from pediatric patients. They were subcultivated, and standardized to perform the test against caspofungin by microdilution technique in 96-well plates, with a RPMI medium with L-glutamine and a pH indicator buffered with MOPS (based on the document NCCLS M27-A2). MIC was defined as the lowest concentration in which there is no growth after 24, 48, and 72 hours of incubation at 35°C and 37°C.
Results. After 48 hours of the assay at 35°C. MIC was 0.615 µg/ml for C. albicans and C. tropicalis. There is no resistance to caspofungin in any of the samples.
Conclusion. We identified the better conditions for the determination of sensibility and MIC of C. albicans and C. tropicalis through the technical of microdilution for caspofungin.
Discussion. Caspofungin has been used as an alternative for the treatment of disseminated fungemias with strains of the genus Candida with resistance to usual treatment. Commonly this type of fungemia is treated with amphotericin B, which presents a range of adverse effects, that echinocandins do not have and exhibit favorable pharmacokinetic properties, depending on the dose.

REFERENCES

1. Hernández Hernández Francisca. “Frecuencia de micosis en pacientes inmunosuprimidos de un hospital regional de la Ciudad de México”. Salud Pública Méx 2003; 45(6): 455-460.

2. Cantón E, Pemán J, Bosch M, Viudes A, Gobernado M. “Actividad del voriconazol sobre levaduras aisladas de hemocultivo determinada por dos métodos”. Rev Esp Quimioter 2005;18:308-312.

3. Saunus JM, Kazoullis A, Farah CS. “Cellular and molecular mechanisms of resistance to oral Candida albicans infections”. Front Biosci 2008;13:5345-58.

4. Claudia Wagner et al. “The Echinocandins: Comparison of Their Pharmacokinetics, Pharmacodynamics and Clinical Applications”. Pharmacology 2006;78:161–177.

5. Sobel JD, and Sanjay G. Revankar. “Echinocandins — First-Choice or First-Line Therapy for Invasive Candidiasis?” N Engl J Med 2007;24 (356):2525-2526.

6. Murray, Patrick R et al. Manual of Clinical microbiology. 9a ed. Washington, DC: ASM Press, 2007, vol. 2, pp. 1954-1971.

7. Jacobsen Mette D; Whyte Julie A; Odds Frank C. “Candida albicans and Candida dubliniensis respond differently to Echinocandin Antifungal Agents In Vitro”. Antimicrobial agents and chemotherapy 2007;5(51):1882–1884.

8. Lichtenstern C, Nguyen TH, Schemmer P, Hoppe-Tichy T, Weigand MA. “Efficacy of caspofungin in invasive candidiasis and candidemia-de-escalation strategy”. Mycoses 2008;(51)Suppl 1:35-46.

9. Kauffman CA, Carver PL. “Update on echinocandin antifungals”. Seminars in Respiratory and Critical Care Medicine 2008;29(2):211-9.

10. Balani SK et al. “Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine”. Drug Metab Dispos 2000;28: 1274-1278.

11. J Stone JA, Holland SD, Wickersham PJ, Sterrett A, Schwartz M, Bonfiglio C, Hesney M, Winchell GA, Deutsch PJ, Greenberg H, Hunt TL, Waldman SA. “Single- and Multiple-Dose Pharmacokinetics of Caspofungin in Healthy Men”. Antimicrob agents and chemother 2002;46(3):739–745.